Rifampin-Induced Loss of Glucocorticosteroid Therapeutic Effect

This publication has 14 references indexed in Scilit:

• Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
  European Journal of Drug Metabolism and Pharmacokinetics, 2023
• 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
  Annals of the Rheumatic Diseases, 2022
• Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management
  Alimentary Pharmacology & Therapeutics, 2022
• Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids
  PLOS ONE, 2020
• Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
  Clinical Infectious Diseases, 2016
• Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
  Autoimmunity Reviews, 2015
• Update on Rifampin Drug Interactions
  Archives of internal medicine (1960), 1987
• Rifampicin and adrenal crisis.
  BMJ, 1983
• Rifampicin reduces effectiveness and bioavailability of prednisolone.
  BMJ, 1983
• Interaction of Rifampin and Glucocorticoids
  JAMA, 1976